NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Soligenix's HyBryte™ Therapy for Cutaneous T-Cell Lymphoma (CTCL)
TL;DR
Soligenix's HyBryte therapy offers investors a strategic advantage by targeting the challenging early-stage CTCL market with a novel, visible light-activated treatment showing significant clinical efficacy.
HyBryte works as a photodynamic therapy using synthetic hypericin activated by visible red-yellow light to target malignant T-cells in skin while minimizing damage to healthy tissue.
This therapy improves patient outcomes by providing a safer, targeted treatment for early-stage CTCL, reducing long-term risks and addressing a critical gap in rare disease care.
Soligenix's visible light therapy represents an innovative shift from traditional ultraviolet treatments, using synthetic hypericin to precisely target cancer cells with minimal collateral damage.
Found this article helpful?
Share it with your network and spread the knowledge!
The article focuses on Soligenix's development of HyBryte™ (synthetic hypericin), a novel photodynamic therapy for treating early-stage cutaneous T-cell lymphoma (CTCL), which addresses critical gaps in rare disease treatment.
CTCL is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages, creating a challenging diagnostic and treatment landscape.
Unlike traditional ultraviolet-based phototherapies that carry long-term safety risks with cumulative exposure, HyBryte™ is activated by visible light in the red-yellow spectrum, allowing targeted treatment of malignant T-cells while minimizing damage to surrounding healthy tissue.
Clinical data reported by Soligenix indicate that HyBryte™ has demonstrated statistically significant efficacy in reducing CTCL lesions in patients with early-stage disease.
Soligenix is a late-stage biopharmaceutical company that has successfully completed a second Phase 3 study and is moving toward potential commercialization of HyBryte™ worldwide, pending regulatory approvals.
Soligenix is expanding synthetic hypericin into psoriasis treatment, developing dusquetide for inflammatory diseases including oral mucositis, and has vaccine programs targeting ricin toxin, filoviruses (Marburg and Ebola), and COVID-19 prevention.
The company's Public Health Solutions business segment has been supported with government grants and contract funding from NIAID, DTRA, and BARDA.
For further information, visit the company's website at www.Soligenix.com or access the latest news and updates at https://ibn.fm/SNGX.
Curated from InvestorBrandNetwork (IBN)
